Drug Approval | March 12, 2026
FDA nod to first treatment for rare genetic brain disorder
The approval comes after a systematic review of published literature
The approval comes after a systematic review of published literature
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Germany will be the first launch market
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Subscribe To Our Newsletter & Stay Updated
